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MicroRNA 29aa b s t r a c t
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is an important regulator of
cell adhesion, invasion, and metastasis. The aim of this study was to evaluate the functional roles of
CEACAM6 in lung adenocarcinoma and to identify miRNAs that inhibit the growth, migration, and
invasion of lung adenocarcinoma cells by targeting CEACAM6. CEACAM6 expression is associated
with poor prognosis of patients with lung adenocarcinoma, and CEACAM6 has important functional
roles in controlling the growth, migration, and invasion of lung adenocarcinoma cells in vitro and
in vivo. Furthermore, miR-29a can suppress the growth, migration, and invasion of lung adenocar-
cinoma cells by targeting CEACAM6. Therefore, miR-29a/CEACAM6 axis represents a potential
therapeutic target for treatment of lung adenocarcinoma.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide, with non-small cell lung cancer (NSCLC) accounting
for 80–85% of cases [1]. Despite improvements in early diagnosis
and recent advances in treatment, the prognosis for patients with
NSCLC remains dismal and the overall 5 year survival rate remains
a disappointing 15% [2]. Although surgery is a potential curative
strategy, a considerable number of patients with NSCLC are
initially diagnosed with unresectable, locally advanced, or meta-
static disease, and the recurrence rate is high even in early stage
groups [3]. Invasion and metastasis, the hallmarks of cancer, are
the primary cause of patient mortality during NSCLC progression.
Invasion refers to the ability of cancer cells to penetrate through
the membranes that separate them from healthy tissues and blood
vessels, and metastasis refers to the spreading of cancer cells toother parts of the body. A number of cell adhesion molecules play
roles as critical regulators of these processes [4].
The carcinoembryonic antigen-related cell adhesion molecule
(CEACAM) protein family has been implicated in various intercellu-
lar adhesion and signaling processes that mediate cellular growth
and differentiation [5,6]. CEACAM6 is a single-chain glycosylphos-
phoinositol-anchored immunoglobulin-like glycoprotein that
mediates homotypic and heterotypic cell–cell interactions with
other CEACAM family molecules through integrin receptors [6–
8]. CEACAM6 is involved in cell adhesion, migration, invasion,
and the metastatic behavior of tumor cells [6,9]. It is overexpressed
in a wide variety of carcinomas, including NSCLC and pancreatic,
colon, breast, gastric, and hepatocellular carcinomas [10–17]. For
NSCLC, lung adenocarcinomas express higher levels of CEACAM6
protein than other histologic subtypes and CEACAM6 expression
is associated with poor clinical outcome of the disease [10,17];
however, the molecular mechanisms that underlie its activities in
lung adenocarcinoma have not yet been elucidated. Regulators of
CEACAM6 expression, such as microRNAs (miRNAs), a family of
endogenous small (approximately 22 nucleotides in length) non-
coding and functional RNAs that regulate the expression of many
genes [18], may have a profound effect on lung adenocarcinoma
progression. Aberrant expression of miRNAs occurs in many types
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or oncogenes [19].
The aim of this study was to evaluate the biological roles of
CEACAM6 in lung adenocarcinoma growth, migration, and invasion
in vitro and in vivo, and to identify miRNAs that inhibit these
processes by targeting CEACAM6.
2. Materials and methods
2.1. Tissue samples
Lung adenocarcinoma tissue samples were obtained from 51
patients undergoing a curative resection at Chungbuk National
University Hospital (Cheongju, South Korea) between January
2003 and December 2011. The following clinical and pathological
characteristics were reviewed: age, sex, histological grading
according to the World Health Organization’s system, and
pathologic staging according to the 7th edition of the tumor-
node-metastasis cancer staging system of the American Joint
Committee on Cancer [2]. This study was reviewed and approved
by the Institutional Review Board of Chungbuk National Univer-
sity Hospital.
2.2. Tissue microarray and immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded specimens were used to
construct a lung adenocarcinoma tissue microarray (TMA). Immu-
nohistochemical (IHC) analyses of 4 lm parafﬁn sections of the
TMA blocks were performed. Fully automated immunostaining
was achieved using a BenchMark XT autostainer (Ventana Medical
Systems Inc., Tucson, AZ, USA). The sections were incubated with a
monoclonal mouse anti-human CEACAM6 antibody (9A6, dilution
1:4000; Santa Cruz Biotechnology Inc., Dallas, TX, USA) for
32 min, followed by Ventana Universal HRP Multimer for 8 min
at 37 C. CEACAM6 expression was scored as follows: score 0, no
staining; score 1+, <10% of tumor cells expressing CEACAM6; score
2+, 10–50% of tumor cells expressing CEACAM6; and score 3+, >50%
of tumor cells expressing CEACAM6. Scores of 0 and 1+ were clas-
siﬁed as low expression of CEACAM6 and scores of 2+ and 3+ were
classiﬁed as high expression.
2.3. Western blot analysis
Proteins were separated by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis and transferred to nitrocellulose mem-
branes (Bio-Rad Laboratories, Hercules, CA, USA). The membranes
were blocked with 5% non-fat milk and then incubated with a
mouse anti-CEACAM6 monoclonal antibody (9A6, Santa Cruz Bio-
technology Inc.) or a mouse anti-b-actin monoclonal antibody
(Sigma, St. Louis, MO, USA) as a loading control. The protein com-
plexes were detected with enhanced chemiluminescence reagents
(Pierce, Rockford, IL, USA).
2.4. Cell proliferation assay
Cell proliferation assays were performed using the Cell Prolifer-
ation Kit II (XTT) (Roche, Indianapolis, IN, USA), according to the
manufacturer’s instructions. The cells were seeded onto 96-well
plates at a density of 1  104 cells/well and incubated for the indi-
cated number of hours. The XTT labeling mixture was prepared by
mixing 50 volumes of 1 mg/ml sodium 30-[1-(phenylaminocarbon-
yl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzenesulfonic acid
hydrate with 1 volume of 0.383 mg/ml N-methyldibenzopyrazine
methyl sulfate. A 50 ll aliquot of XTT labeling mixture was subse-
quently added to each well and the cells were incubated for 2 h at
37 C. Absorbance was measured at 495 and 650 nm was used as a
reference wavelength.2.5. Cell migration and invasion assays
Cell migration analyses were performed using wound healing
assays. The cells were plated into low 35 mm l-dishes containing
culture inserts (Ibidi, Martinsried, Germany). The inserts were
removed with sterile forceps to create a wound ﬁeld of approxi-
mately 500 lm when the cells were conﬂuent. The cells were then
allowed to migrate in an incubator. At 0 and 24 h, three ﬁelds of the
injury area were photographed with a light microscope at 100
magniﬁcation. For each image, the area that was uncovered by cells
was determined by analysis with Image Pro Plus 4.5.1 software. For
the invasion assays, 105 cells in serum-free medium were placed
into the top chamber of each insert coated with 150 lg Matrigel
(BD Biosciences, Franklin Lakes, NJ, USA). After incubation at
37 C for 24 h, cells adhering to the lower membrane were stained
with 0.1% crystal violet in 20% methanol, imaged, and then ten dif-
ferent ﬁelds of each ﬁlter were manually counted at 200
magniﬁcation.
2.6. Luciferase reporter assay
Luciferase reporter assays were performed using the Dual-
Luciferase Reporter Assay System (Promega), according to the
manufacturer’s instructions. Transfections were performed in 48-
well plates using Lipofectamine 2000 reagent (Invitrogen). At
48 h post-transfection, the culture medium was removed, the cells
were washed twice with cold PBS, and then 50 ll of Passive Lysis
Buffer (Promega) were added to each well. A 10 ll aliquot of the
lysate was analyzed using a GloMax microplate luminometer (Pro-
mega). Renilla luciferase activity was measured and normalized to
that of ﬁreﬂy luciferase, which was used as an internal control.
2.7. In vivo tumor xenograft experiments
Control cells or A549 cells that were stably transfected with the
indicated CEACAM6-speciﬁc shRNA or miR-29a expressing vector
were subcutaneously injected into the right ﬂank of 6-week-old
BALB/c athymic nude mice (seven mice per group, 9  106 cells/
mouse). Tumor growth was determined every 2 or 3 days for
4 weeks by measuring the length (L), width (W), and height (H)
with calipers and using the formula V = (L W  H)  0.5. All ani-
mal work was performed in accordance with a protocol approved
by the Institutional Animal Care and Use Committee of Korea
Research Institute of Bioscience and Biotechnology.
2.8. Statistical analysis
All data are representative of experiments that were repeated at
least three times with similar results on each separate occasion.
The data are represented as the mean ± standard deviation. Stu-
dent t-tests were used for comparisons between groups and the
Chi-square test was used for categorical variables. Survival curves
were estimated using the Kaplan–Meier method and compared
using the log rank test. P < 0.05 was considered statistically signif-
icant. All statistical analyses were performed using SPSS software
for Windows, version 15.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. CEACAM6 expression is associated with the overall survival of lung
adenocarcinoma patients
IHC staining of human lung adenocarcinoma specimens
revealed that CEACAM6 was localized mainly to the cytoplasm of
tumor cells (Fig. 1A). Staining was absent or sporadic in non-
neoplastic lung tissue, which was used as negative control
Fig. 1. CEACAM6 expression in lung adenocarcinoma specimens and its relation-
ship to overall survival. (A) Immunohistochemical analysis of a representative lung
adenocarcinoma specimen showing positive staining for CEACAM6 (magniﬁcation,
200). (B) Immunohistochemical analysis of a representative normal lung tissue
specimen showing negative staining for CEACAM6 (magniﬁcation, 400). (C)
Kaplan–Meier estimates of overall survival classiﬁed according to the CEACAM6
expression level identiﬁed by IHC staining (low expression, scores of 0 and 1+; high
expression, scores of 2+ and 3+). HR, hazard ratio; CI, conﬁdence interval.
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(86.3%) of the 51 lung adenocarcinoma specimens examined. The
tumor specimens were divided into two groups according to theFig. 2. CEACAM6 enhances the proliferation, migration, and invasion of lung adenocar
CEACAM6-targeting shRNAs (B12 and G1). The expression level of b-actin was used as an
A549 cells transfected with the G1 CEACAM6-speciﬁc shRNA. (C) Wound healing assays to
assays of control, B12 shRNA-expressing, and G1 shRNA-expressing A549 cells. (E) Weste
The proliferation (F), migration (G), and invasion (H) of control A549 cells and A549 cells o
t-tests and the data are represented as the mean ± S.D. ⁄P < 0.05.IHC staining score; overall, 39 (76.5%) and 12 (23.5%) specimens
showed high (score of 2+ or 3+) and low (score of 0 or 1+) CEA-
CAM6 expression, respectively. The level of CEACAM6 expression
was not signiﬁcantly correlated with age, sex, differentiation, or
pathologic stage (Supplementary Table 1). However, patients with
low CEACAM6 expression had signiﬁcantly longer overall survival
times than those with high CEACAM6 expression. The median
overall survival times for the low and high expression group were
100.7 months (95% conﬁdence interval, 42.2–100.7) and
35.1 months (95% conﬁdence interval, 22.2–50.9), respectively
(hazard ratio for death, 0.36; 95% conﬁdence interval, 0.16–0.82;
P = 0.046) (Fig. 1C).
3.2. CEACAM6 enhances the proliferation, migration, and invasion of
lung adenocarcinoma cells in vitro
To examine the biological function of CEACAM6 in lung adeno-
carcinoma, two different CEACAM6-targeting shRNAs (B12 and G1)
were designed and transfected into A549 cells. The G1 shRNA
reduced the expression of CEACAM6 more effectively than the
B12 shRNA (Fig. 2A) and was used in further analyses. Knockdown
of CEACAM6 suppressed the proliferation (Fig. 2B), migration
(Fig. 2C), and invasion (Fig. 2D) of the A549 cells signiﬁcantly. To
verify these results, the effect of overexpression of exogenous CEA-
CAM6 on the proliferation, migration, and invasion of lung adeno-
carcinoma cells in vitro was also examined. In support of the
shRNA studies, overexpression of CEACAM6, which was conﬁrmed
by Western blot analysis (Fig. 2E), increased the proliferation
(Fig. 2F), migration (Fig. 2G), and invasion (Fig. 2H) of the A549
cells signiﬁcantly.
3.3. Knockdown of CEACAM6 inhibits the growth of lung
adenocarcinoma tumors in vivo
To conﬁrm the results of the in vitro study, A549 cells express-
ing the CEACAM6-speciﬁc shRNA (or empty vector as a control)
were subcutaneously injected into the right ﬂank of nude mice,
which were sacriﬁced 4 weeks after injection. Tumor outgrowth
and size were reduced in CEACAM6-deﬁcient tumor-bearing mice,
but control mice displayed visible tumors 10 days after injectioncinoma cells in vitro. (A) Western blot analyses of CEACAM6 in the two different
internal loading control. C, control. (B) The proliferation of control A549 cells and
evaluate the migration of control and G1 shRNA-expressing A549 cells. (D) Invasion
rn blot analyses of CEACAM6 in the control (C) and CEACAM6-expressing cells. (F–H)
verexpressing exogenous CEACAM6. Statistical analyses were performed by Student
Fig. 3. Knockdown of CEACAM6 inhibits the growth of lung adenocarcinoma tumors in vivo. (A) Tumor growth in mice subcutaneously injected with A549 cells expressing
the CEACAM6-speciﬁc shRNA or empty vector as a control. (B) Western blot analysis of CEACAM6 expression in the control (C) and CEACAM6-speciﬁc shRNA-expressing A549
tumors. The expression level of b-actin was used as an internal loading control. (C) Representative image of tumors from nude mice 4 weeks after injection of 9  106 control
or CEACAM6-speciﬁc shRNA-expressing A549 cells.
H.S. Han et al. / FEBS Letters 588 (2014) 3744–3750 3747and tumor growth in these mice was exponential for the 4 weeks
observation period (Fig. 3A–C). These results indicate that knock-
down of CEACAM6 in lung adenocarcinoma cells can inhibit tumor
growth in vivo.
3.4. MiR-29a targets CEACAM6 directly in lung adenocarcinoma
A target prediction program (TargetScanHuman 6.2) was used
to identify putative miRNA-binding sites in the 30 UTR of humanFig. 4. MiR-29a targets CEACAM6 directly in lung adenocarcinoma cells. (A) Alignment
binding sites (red). The vertical lines indicate identity and the gaps indicate mismatches
cells with a miR-16 mimic, miR-29a mimic, or miR-29a inhibitor. The expression level o
luciferase activity assays of A549 cells co-transfected with a reporter vector containing th
control. The activity of Renilla luciferase was normalized to that of ﬁreﬂy luciferase. Stati
mean ± S.D. ⁄P < 0.05.CEACAM6, and miR-29a and miR-16 were selected as candidates
for further analysis. The 30 UTR of CEACAM6 contains two putative
binding sites for miR-29a (Fig. 4A). To examine the roles of these
miRNAs as potent regulators of CEACAM6 expression, A549 cells
were transfected with a miR-16 mimic, miR-29a mimic, or a nega-
tive vector mimic. Western blot analyses showed that, compared
with the negative vector-transformed cells, those overexpressing
miR-29a had signiﬁcantly lower expression levels of endogenous
CEACAM6. In support of this ﬁnding, transfection of the cells withof the miR-29a sequence with that of the 30 UTR of CEACAM6 showing the putative
. (B) Western blot analyses of CEACAM6 expression 48 h after transfection of A549
f b-actin was used as an internal loading control. NC, negative control. (C) Relative
e wild-type (wt) or mutant (mt) 30 UTR of CEACAM6 and a miR-29a mimic or vector
stical analysis was performed by Student t-test and the data are represented as the
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(Fig. 4B). By contrast, the CEACAM6 protein level was not affected
by overexpression of miR-16 (Fig. 4B).
Next, a luciferase reporter assay was performed to conﬁrm that
CEACAM6 is a direct target of miR-29a. In these experiments, A549
cells were co-transfected with a vector containing the 30 UTR of
CEACAM6 directly downstream of a luciferase reporter, and a vector
containing miR-29a or a control miRNA. Compared with that in the
control cells, the relative luciferase activity was signiﬁcantly lower
in the cells co-transfected with miR-29a, whereas it was not
affected by co-transfection with a mutant CEACAM6 30 UTR in
which the putative miR-29a binding sites were disrupted
(Fig. 4C). These results indicate that miR-29a can down-regulateFig. 5. MiR-29a suppresses the proliferation, migration, and invasion of lung adenocarcin
with a miR-29a mimic or a negative control vector. (C) Invasion assays of control (C) cel
miR-29a mimic. Statistical analyses were performed by Student t-tests and the data are
Fig. 6. MiR-29a inhibits the growth of lung adenocarcinoma tumors in vivo. (A) Tumor
expressing cells. (B) Real-time RT-PCR analyses of miR-29a and Western blot analyses
expressing cells (A549/C) or miR-29a-expressing cells. The expression level of b-actin w
analyses. Statistical analyses were performed by Student t-tests and the data are repres
mice 4 weeks after injection of 9  106 control vector-expressing or miR-29a-expressingthe expression of CEACAM6 by binding directly to its 30 UTR,
suggesting that CEACAM6 may be a downstream target of miR-
29a in lung adenocarcinoma cells.
3.5. MiR-29a suppresses the proliferation, migration, and invasion of
lung adenocarcinoma cells in vitro
To investigate the function of miR-29a in lung adenocarcinoma
cells, in vitro proliferation, migration, and invasion assays of
control A549 cells and A549 cells expressing a miR-29a mimic
were performed. Overexpression of miR-29a decreased the prolif-
eration activity (Fig. 5A) and migratory ability (Fig. 5B) of the cells
signiﬁcantly. In the invasion analyses, the transwell assays wereoma cells in vitro. (A, B) The proliferation (A) migration (B) of A549 cells transfected
ls and cells transfected with a miR-29a inhibitor alone or a miR-29a inhibitor and a
represented as the mean ± S.D. ⁄P < 0.05.
growth in mice injected with control vector-expressing cells (A549/C) or miR-29a-
of CEACAM6 expression in A549 tumors from mice injected with control vector-
as used as an internal loading control in both real-time RT-PCR and Western blot
ented as the mean ± S.D. ⁄P < 0.05. (C) Representative images of tumors from nude
cells.
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decrease the expression of the endogenous miRNA. The results
showed that overexpression of the miR-29a mimic suppressed
the invasion ability of the cells signiﬁcantly and inhibition of
miR-29a enhanced this ability signiﬁcantly (Fig. 5C). These results
indicate that miR-29a may suppress the proliferation, migration,
and invasion of lung adenocarcinoma cells by targeting CEACAM6.
3.6. MiR-29a inhibits the growth of lung adenocarcinoma tumors
in vivo
After transfection with empty vector or a vector expressing
miR-29a, a xenograft of A549 cells was subcutaneously injected
into the dorsal ﬂank of nude mice and tumor volumes were calcu-
lated after the mice developed palpable tumors. At 4 weeks post-
injection, the volumes of the xenografts were smaller in mice that
received miR-29a-transfected cells than those that received control
A549 cells (Fig. 6A–C). These results demonstrate that treatment of
lung adenocarcinoma cells with miR-29a can inhibit tumor growth
by suppressing CEACAM6 expression in vivo.
4. Discussion
In the present study, CEACAM6 expression is associated with
poor prognosis of patients with lung adenocarcinoma, and we
demonstrate that CEACAM6 has important functional roles in
controlling the growth, migration, and invasion of lung adenocarci-
noma cells in vitro and in vivo. Furthermore, the data indicate that
miR-29a suppresses lung adenocarcinoma growth, migration, and
invasion by targeting CEACAM6.
CEACAM6 inhibits anoikis (apoptosis induced by inadequate
adhesion to the surrounding extracellular matrix) and modulates
the malignant phenotype of cancer cells [20,21]. Anoikis resistance
conferred by CEACAM6 expression results in cell survival under
anchorage-independent conditions and is a characteristic associ-
ated with tumorigenesis and metastasis. CEACAM6 is expressed
at low levels in normal epithelial, endothelial, and hematopoietic
cells, including granulocytes and monocytes [13,22]. By contrast,
CEACAM6 expression is up-regulated in many epithelial malignan-
cies, including pancreatic, colorectal, breast, gastric, and lung ade-
nocarcinomas, and its overexpression is associated with poor
clinical outcomes [10–17]. In pancreatic cancer cells, overexpres-
sion of CEACAM6 is associated with anoikis resistance, metastasis,
and gemcitabine resistance [11,21,23,24]. Furthermore, overex-
pression of the protein is correlated with reduced survival and
the development of metastasis in colorectal cancer patients
[9,14,25], and is a signiﬁcant predictor of recurrence in breast can-
cer [26]. Regarding lung adenocarcinoma, CEACAM6 acts as an
inducer of cell proliferation in A549 cells and increased serum lev-
els of CEACAM6 are frequently detected in patients with lung ade-
nocarcinoma [16]. Moreover, CEACAM6 expression is signiﬁcantly
associated with adverse clinical outcomes of lung adenocarcinoma
patients [17]. In agreement with these ﬁndings, CEACAM6 was
expressed at a high level in most of the 51 lung adenocarcinoma
tissue samples examined here, and elevated expression of the pro-
tein was associated with poor prognosis of the patients. Further-
more, overexpression of CEACAM6 functionally enhanced the
growth, migration, and invasion of lung adenocarcinoma cells both
in vitro and in vivo. RNA interference-mediated knockdown of
CEACAM6 decreased the proliferation, migration, and invasion of
A549 cells, whereas its overexpression increased the proliferation,
migration, and invasion of transfected cells in vitro. These ﬁndings
are consistent with the results of the in vivo mouse xenograft
experiments, in which knockdown of CEACAM6 inhibited the
growth of lung adenocarcinoma tumors.The results presented here indicate that miR-29a acts as a
tumor suppressor in lung adenocarcinoma by targeting CEACAM6
directly. Overexpression of miR-29a suppressed cell proliferation,
migration, and invasion in vitro and inhibited the growth of lung
adenocarcinoma tumors in vivo. In addition, overexpression of this
miRNA induced a signiﬁcant downregulation of CEACAM6 protein
expression and suppressed the activity of a luciferase reporter
fused to the 30 UTR of CEACAM6. The human miR-29 family com-
prises miR-29a, miR-29b, miR-29c, and miR-29d [27,28]. Members
of this family have been described as tumor suppressor genes and
their expression levels are down-regulated in several cancers [27–
32]. Although the detailed functional mechanisms of these miRNAs
that are relevant to cancer are poorly understood, a number of pre-
vious studies have revealed that they target genes involved in cell
proliferation and the cell cycle, cell senescence, differentiation,
apoptosis, and metastasis at genetic and epigenetic levels in vari-
ous types of cancer [27,28]. As a tumor promoter, miR-29 mediates
epithelial–mesenchymal transition and promotes metastasis in
breast and colon cancers [28,33], indicating that the function and
targets of miR-29 are context dependent. MiR-29a expression is
reduced in NSCLC, and it has a signiﬁcant anti-invasive and anti-
proliferative effect on lung cancer cells in vitro [34]: this function
is likely mediated through direct and indirect post-transcriptional
ﬁne tuning of the cellular levels of several proteins. The expression
levels of miR-29a and miR-29b in lung cancer are regulated by
DNA methyltransferases (DNMTs) 3A and 3B (de novo methyl-
transferases), which alter the epigenetic modiﬁcations of chroma-
tin and inhibit tumor suppressor gene expression. These DNMTs
are frequently up-regulated in lung cancer and are associated with
poor prognosis [35]. Suppression of DNMT3A and DNMT3B
restores the expression of Wnt inhibitory factor-1, which is
silenced by promoter methylation in NSCLC [36], and miR-29a,
miR-29b, and miR-29c suppress the Wnt signaling pathway
through demethylation of Wnt inhibitory factor-1 in NSCLC [36].
Furthermore, miR-29a has a tumor suppressive role in restricting
the activity of DNA damage responsive kinases such as Cdc7 in
lung cancer cells [37]. Recently, Chen et al. reported that CEACAM6
directly impacts the epithelial–mesenchymal transition, migration,
invasion, and metastasis of pancreatic cancer cells, and showed
that miR-29a/b/c can regulate CEACAM6 at the post-transcriptional
level in pancreatic cancer [24]. Therefore, miR-29a may act as a
tumor suppressor in lung adenocarcinoma and pancreatic cancer
by inhibiting the expression of CEACAM6.
In conclusion, the results presented here demonstrate that miR-
29a can suppress the growth, migration, and invasion of lung ade-
nocarcinoma cells by targeting CEACAM6. The miR-29a/CEACAM6
axis provides a new insight into the pathogenesis of lung adenocar-
cinoma and represents a potential therapeutic target for treatment
of the disease.
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